Open an account

Olema Pharmaceuticals

OLMA · NASDAQ

$7.25+$0.14 (+1.97%)TodayMarket closed ·
Prev close $7.11

About OLMA

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 131 full-time employees. The company went IPO on 2020-11-19. The firm is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. The company is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

Employees
131
Headquarters
San Francisco, California
Listed
Nov 19, 2020
Sector
Health Care
Industry
Biotechnology
Website
olema.com

OLMA key statistics

Market cap
634.36M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.26M
Volume
1.87M
Open price
$7.12
High today
$7.61
Low today
$7.09
52 Week high
$36.26
52 Week low
$6.48

Olema Pharmaceuticals (OLMA) at a glance

Olema Pharmaceuticals (OLMA) last traded at $7.25, with a market cap of 634.36M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.09 and $7.61. The current price is 2.3% above the day's low and 4.7% below its high.

Volume so far is 1.87M shares, above the average of 1.26M shares a day.

Over the past year Olema Pharmaceuticals has ranged from $6.48 to $36.26, and now sits 3% of the way up that range.

Olema Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.61 per share against an estimate of -$0.5554.

The average analyst price target is $36.15, 398.7% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

91%of 11 analyst ratings say Buy
  • Buy90.9%
  • Hold9.1%
  • Sell0.0%
Price target · 12 analystsAvg $36.15
Low
$16.16
Now
$7.25
High
$61.95

OLMA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 12.8% on average.

  1. Q3 FY24: reported -$0.60 per share against an estimate of -$0.5894
  2. Q4 FY24: reported -$0.51 per share against an estimate of -$0.6528
  3. Q1 FY25: reported -$0.36 per share against an estimate of -$0.5202
  4. Q2 FY25: reported -$0.51 per share against an estimate of -$0.3835
  5. Q3 FY25: reported -$0.49 per share against an estimate of -$0.4933
  6. Q4 FY25: reported -$0.50 per share against an estimate of -$0.5393
  7. Q1 FY26: reported -$0.52 per share against an estimate of -$0.5394
  8. Q2 FY26: reported -$0.61 per share against an estimate of -$0.5554

OLMA news

  • Vandana Singh

    Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releaseGlobe Newswire

    Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

  • Vandana Singh

    What's Going On With Olema Pharmaceuticals Stock On Wednesday?

  • Press releaseBusiness Wire

    Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA

  • Vandana Singh

    Why Is Olema Pharmaceuticals Stock Dropping On Monday?

  • Avi Kapoor

    Dow Tumbles Over 600 Points; Korn Ferry Posts Upbeat Earnings

  • Avi Kapoor

    Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday

Similar companies

Companies in the same industry as Olema Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.